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Introduction
Kidney disease is a significant health problem for 
all Australians, but severe kidney disease is more 
common among Indigenous people than among non-
Indigenous people [1, 2]. In particular, the prevalence 
of chronic kidney disease (CKD) (Box 1) [2-6] and the 
overall levels of end-stage kidney disease (ESKD) 
among Aboriginal and Torres Strait Islander peoples 
are consistently reported as significantly higher than 
among other Australians [4, 7].
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Box 1. Chronic kidney disease and end-
stage kidney disease
Chronic kidney disease (CKD) is defined as kidney damage or 
reduced kidney function that lasts for three months or more 
[7-9]. Diabetes (diabetic nephropathy) and high blood pressure 
are the most common causes of CKD; other causes include 
glomerular disease, inherited disorders (such as polycystic 
kidney disease), and hypertensive renal disease. 
The most severe form of chronic kidney disease, known as 
end-stage kidney disease (ESKD; also known as end-stage renal 
disease (ESRD)), occurs when kidney function has decreased to 
the point where kidney replacement therapy (KRT) is necessary 
to avoid death. KRT involves either dialysis (mechanical filtering 
of the blood to help maintain functions normally performed by 
the kidneys) or transplantation (implantation of a kidney from 
either a living or recently deceased donor). (See also Box 8.)
CKD is expensive to treat and has a marked impact on the 
quality of life of those who suffer from the disease as well as 
those who care for them [7, 8].
Information on CKD among Indigenous Australians is available 
from self-reported survey data, as well as from community-based 
studies and screening programs [10-20] but the main focus in the 
literature has been on ESKD [4, 7]. The incidence of ESKD is especially 
high for Indigenous people living in remote and very remote areas 
of Australia [Derived from 5] with rates of ESKD highest in northern 
Australian Indigenous communities [4, 6, 21, 22].
People with CKD require extensive hospital services, particularly 
those patients with ESKD who require kidney replacement 
therapy (KRT) to survive. As such, CKD is a significant cause of 
hospitalisation for the Indigenous Australian population [23]; this 
is particularly the case for dialysis, the form of KRT on which far 
greater proportions of Indigenous people with ESKD than their 
non-Indigenous counterparts rely [4]. In 2009-10, care involving 
dialysis was the most common reason for the hospitalisation of 
Indigenous Australians: they were hospitalised at 11 times the rate 
of other Australians [24].
Indigenous people have substantially higher death rates than 
other Australians from most causes [25, 26] and diseases of the 
kidney and urinary system are one of the top ten leading causes 
of death overall, for all Australians, including Indigenous people 
[25]. Indigenous people are more likely to die from kidney disease 
that non-Indigenous people, with the death rate ratios being 
particularly high after the age of 25 years for both Indigenous 
males and females compared with rates for non-Indigenous 
Australians [7, 27].
About this review
The purpose of this review is to provide an overview of the 
burden of kidney disease among Indigenous Australians. After 
summarising kidney disorders and the context of kidney disease 
among the general Australian population, attention is directed 
to the factors contributing to kidney disease among Indigenous 
people. The extent of CKD and ESKD among Indigenous people 
in Australia is then addressed by outlining the overall incidence 
and prevalence, and associated hospitalisation and mortality. The 
review also outlines the extent of other urologic conditions and 
disorders of the urinary tract among Indigenous people, including 
acute post-streptococcal glomerulonephritis (APSGN), urinary 
tract infections (UTIs) and urolithiasis. The factors contributing to 
kidney health problems, particularly CKD and ESKD, are considered 
in the context of the management and treatment of these 
conditions. The review concludes by outlining the current policies 
and strategies employed to address kidney health in Australia, with 
particular focus on polices and strategies employed to address the 
kidney health of Indigenous Australians.
Kidney disorders
‘Kidney disease’, ‘renal disease’ and ‘renal disorder’ are collective 
terms that refer to a variety of different renal and urologic disease 
processes involving damage to the working units of the kidneys 
and also includes conditions affecting the function of the body’s 
urinary system, involving the ureters, bladder and urethra [9]. The 
loss of kidney function (Box 2) can have a serious impact on the 
body, causing damage to other organs and bodily processes and, 
as a result, a number of complications and co-morbidities often 
occur, including: heart disease; infections; as well as problems with 
bones and muscles [7, 28].
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Box 2. The kidneys and their function
The two kidneys, parts of the urinary tract system, regulate the 
mineral composition, water content and acidity of the body 
[9]. They are also involved in the excretion of metabolic waste 
products and chemicals, are responsible for the production 
of certain hormones and vitamins, and also have a key role in 
blood pressure regulation. Removal of wastes occurs in tiny 
units inside the kidney known as nephrons; inside each nephron 
is a glomerulus which acts as a sieve-like filtering unit keeping 
proteins and cells in the bloodstream while allowing wastes to 
pass through. These wastes and any extra water become urine, 
which passes through tubes called the ureters into the bladder 
where it is stored until released during urination. Damage to 
the working units of the kidneys results in a reduction in the 
filtering capacity of one or both kidneys [9, 29]. Progressive or 
repeated damage ultimately leads to a point where the kidneys 
are unable to maintain life, leading to death from ESKD unless a 
form of renal replacement therapy (dialysis or transplantation) 
is used.
Due to the commonality of the risks factors for other chronic 
diseases (such as diabetes, hypertension and other cardiovascular 
disease), kidney disease often occurs with concurrent or co-existing 
conditions [7, 29, 30]. Co-morbidities can appear or be worsened 
because of CKD, or they can arise independently. They contribute 
greatly to the development of CKD and ESKD [10, 12, 29]. Treatment 
required for those who have reached the stage of ESKD involves 
KRT (also known as renal replacement therapy (RRT)), involving 
transplantation of the kidney or dialysis [9, 23]. 
Other important kidney and urologic disorders include APSGN, 
UTIs, and urolithiasis [31-34]. The unusual epidemiology of 
urolithiasis within Indigenous communities and the potential 
for recurrent or persistent UTIs to trigger more serious kidney 
damage when coupled with conditions such as diabetes [38], have 
earmarked these urologic conditions as important health issues 
also [38-40].
Context of chronic kidney disease in 
Australia
In Australia, the three major causes for ESKD since 2005 have been 
diabetes, glomerulonephritis (diseases where there is inflammation 
of the glomeruli) and renovascular disease/hypertension [4, 35-37]. 
Abnormal lipid metabolism, proteinuria, sleep apnoea, mineral and 
bone disorder, anaemia, dietary protein restriction, poor nutrition, 
uraemia, acidosis, hyperkalaemia, restless legs, and depression 
are some of the other associated problems with impairment in 
kidney function [29]. The risk of such complications progressively 
increases as kidney function declines [28]. 
Factors contributing to kidney disease 
among Indigenous Australians
Factors contributing to kidney disease among Indigenous people 
are complex. They reflect a combination of broad historical, social, 
cultural, and economic factors, as well as the more commonly 
described proximal biomedical risk factors. The importance of 
historical, psychosocial and socioeconomic aspects is recognised, 
but it is beyond the scope of this review to address these factors in 
any great detail. It is also beyond the scope of the review to address 
comorbidity with diseases such as diabetes, which is recognised 
as an important contributing risk factor. As a result, the main risk 
factors addressed in this review are behavioural and biomedical 
risk factors. 
Historical and socioeconomic context
The current health disadvantages experienced by Indigenous 
people can be linked to social disadvantages and should be 
viewed within a broad historical context [41, 42]. The kidney health 
of Indigenous people has been affected by changes to their once 
active lifestyles and roles, brought about by displacement and 
colonisation by European settlers [43-46]. The reduction in activity 
levels of Indigenous people over time, coupled with poor nutrition 
resulting from displacement by Europeans, has become embedded 
in the social foundations and reflected in the social determinants 
of health [47]. This has played a part in the development of kidney 
disease and other chronic conditions such as diabetes over time, 
particularly in the later part of the 20th Century [45]. 
In addition to the modifiable risk factors (i.e. diet, obesity) for 
kidney health and other chronic conditions impacted by changes 
to the roles of Indigenous people [43, 45, 48], inadequate social 
and economic circumstances also underlie the generally poor 
health status of many Indigenous people and contribute to the 
high rates of kidney and urinary tract disorders in many Indigenous 
communities. Factors relating to the health-care system and 
government policies include limited access to primary and other 
medical care [49, 50]. Sub-standard living conditions, inadequate 
environmental sanitation and poverty also play major contributing 
roles [7, 50]. In Indigenous communities, prevention, control and 
management of kidney disease and associated disorders will 
depend not only on effective, acceptable treatment, but also on 
preventive action to address the poor socioeconomic conditions 
that underlie these conditions [51-55]. 
Behavioural and biomedical risk factors
The factors contributing to kidney disease among Indigenous 
people are generally attributed to various combinations of multiple 
risk factors including: repeated infections, high blood pressure, 
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obesity [7, 56], low birth weight [57, 58], infant malnutrition [59-
61], engagement in high risk behaviours that can adversely affect 
health (e.g. poor diet, low activity levels, alcohol and tobacco use) 
[1, 2, 50] and diabetes [2, 4]. These conditions are quite common 
among Indigenous people, particularly Indigenous women, and 
contribute to high rates of kidney disease [2, 23, 56]. Given the 
modifiable nature of a majority of these factors, efforts to minimise 
these risks can help to reduce the prevalence of kidney disease and 
its associated mortality.
Extent of CKD and end-stage 
kidney disease (ESKD) among 
Indigenous people
Incidence and prevalence
As noted previously, the level of CKD is higher among Aboriginal 
and Torres Strait Islander people than among other Australians 
[2-6]. With no large-scale Indigenous biomedical survey available, 
it is necessary to rely on self-reported survey data as well as 
information from community-based reports and screening 
programs to estimate the prevalence of CKD among Indigenous 
people [10-20, 28]. The most recent self-reported information 
available is from the 2004-05 National Aboriginal and Torres Strait 
Islander Health Survey (NATSIHS) with comparable data for non-
Indigenous people available from the 2004-05 National Health 
Survey (NHS) [1, 27, 28, 62].
In 2004-2005, kidney disease was reported by 2% of Indigenous 
people overall1 [1, 2]. After age-adjustment, kidney disease was 
ten times more common among Indigenous people than among 
non-Indigenous people [1, 2, 27]. The prevalence of kidney disease 
for Indigenous people increased with age, from less than 1% in the 
0-14 age group to 7% for Indigenous people aged 55 years and 
over (see Figure 1) [1]. Except for the 0-14 years age group, kidney 
disease was much more common among Indigenous people than 
among non-Indigenous people across all age groups. The level 
of kidney disease reported in the 2004-2005 NATSIHS was nearly 
twice that reported in 2001 [1, 2, 27].
1	 The	NATSIHS	collected	information	from	people	living	in	private	
dwellings	and	did	not	include	people	in	health	care	facilities,	so	may	
underestimate	the	prevalence	of	kidney	disease	in	the	Indigenous	
population.	
Figure 1.  Prevalence of kidney disease, by Indigenous status and age, 
Australia 2004-2005
0
1
2
3
4
5
6
7
8
Non-Indigenous
Indigneous
55+45-5435-4425-3415-240-14
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(%)
Source: [1].
Detailed information about CKD is only available from periodic 
health surveys, but progression to ESKD is reported routinely to 
the Australia and New Zealand Dialysis and Transplant Registry 
(ANZDATA), which collates the data and produces annual 
surveillance reports [4, 7, 63]. These reports reveal that the overall 
incidence of ESKD is consistently significantly higher among 
Indigenous people than among non-Indigenous people [3, 4].
A total of 675 Indigenous people were newly identified with ESKD 
between 2007 and 2009 – the age-standardised notification rate 
of 960 per 1,000,000 population for Indigenous people was almost 
10 times the rate of 97 per 1,000,000 for non-Indigenous people 
(Table 1) [Derived from 64, 65-67]. Incidence rates of ESKD were 
higher for Indigenous people than for non-Indigenous people 
in all states and territories, with the highest rates recorded for 
Indigenous people living in the NT (1,594 per 1,000,000), WA (1,194 
per 1,000,000), and SA (876 per 1,000,000).
Table 1. Incidence and age-standardised incidence rates for end-stage 
kidney disease, by Indigenous status, and Indigenous:non-
Indigenous rate ratios, selected jurisdictions, Australia, 
2007-2009
Jurisdiction Indigenous Non-
Indigenous
Rate 
ratio
Number Rate Number Rate
NSW 80 283 2,200 98 2.9
Vic 19 415 1,601 101 4.1
Qld 167 637 1,318 106 6.0
WA 156 1,194 605 97 12.4
SA 44 876 503 107 8.2
NT 201 1,594 36 89 18.0
Australia 675 960 6574 97 9.9
Source: [Derived from 64-66, 67].
Notes:
 1 Rates per 1,000,000 population have been standardised using the 
ERP from 30 June 2001.
 2 Rate ratio is the Indigenous rate divided by the non-Indigenous rate.
 3 Incidence rates for Tas and the ACT have not been shown separately 
because of the small numbers of notifications, but are included in 
the figures for Australia.
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More than three-fifths (63%) of Indigenous people newly registered 
with ANZDATA in the period 2007-2009 were aged less than 55 
years, compared with less than one-third (30%) of non-Indigenous 
people registered [Derived from 64-66, 67] (Table 2). Age-specific 
notification rates were higher for Indigenous people than for 
non-Indigenous people across all age groups except those aged 
0-14 years. Rate ratios were particularly high for people aged 35-44 
years (12.6) and 45-54 years (14.3).
Table 2. Incidence and age-standardised incidence rates of end-stage 
kidney disease, by Indigenous status and age group, and 
Indigenous:non-Indigenous rate ratios, Australia, 2007-2009
Age 
(years)
Indigenous Non-Indigenous Rate 
ratioNumber Rate Number Rate
0-14 1 2 83 7 0.2
15-24 12 37 155 18 2.1
25-34 48 214 313 36 5.9
35-44 143 703 507 56 12.6
45-54 222 1,528 932 107 14.3
55-64 183 2,239 1,360 190 11.8
65-74 59 1,670 1,667 375 4.5
75+ 7 438 1,557 390 1.1
All ages 675 960 6,574 97 9.9
Source: Derived from [64-67].
Notes:
 1 Rates per 1,000,000 population.
 2 Rate ratio is the Indigenous rate divided by the non-Indigenous rate.
The high rates of ESKD are a major public health problem for 
Indigenous people, particularly those living in remote parts of the 
country. In 2006-2008, the incidence of ESKD varied greatly with 
remoteness [5]. The incidence of ESKD for Indigenous people was 
especially high in remote and very remote areas of Australia with 
rates almost 18 times and 20 times those of their non-Indigenous 
counterparts (Table 3).
Table 3. Standardised incidence rates of end-stage kidney disease, by 
Indigenous status, rate ratios, and remoteness, 2006-2008
Remoteness Indigenous  
(No. per 
100,000)
Non-Indigenous 
(No. per 
100,000)
Rate ratio
Major cities 40 11 3.6
Inner regional 40 9 4.3
Outer regional 98 9 11.3
Remote 149 8 17.7
Very remote 168 9 19.9
Australia 80 10 8.0
Source: Derived from [5]. 
Notes:
 1 Calendar year reporting. Data are presented in three-year groupings 
because of small numbers each year.
 2 Directly age-standardised using the Australian 2001 standard 
population. Age standardised rates have been calculated using the 
direct method, age standardised by five year age group to 65+.
 3 Rate ratio is Indigenous rate divided by non-Indigenous rate.
 4 Australia total includes cases where remoteness category was not 
known.
The full extent of ESKD among Indigenous people is reflected by 
the far greater proportion of Indigenous people reliant on dialysis 
for KRT compared with their non-Indigenous counterparts [4]. As 
at 31 December 2008, of all Indigenous ESKD patients registered 
with ANZDATA, 88% relied on dialysis compared with 55% of 
non-Indigenous Australians [5]. Only 12% of Indigenous people 
had received a kidney transplant, compared with 45% of their non-
Indigenous counterparts.
Hospitalisation
A recent report on hospitalisation confirms that Indigenous people 
are admitted to hospital much more frequently for CKD and ESKD 
than are non-Indigenous Australians [23]. In 2009-10, care involving 
dialysis was the most common reason for the hospitalisation (Box 
3) of Indigenous people living in NSW, Vic, Qld, WA, SA and the NT, 
with Indigenous people hospitalised 11 times more often than were 
their non-Indigenous counterparts [24]. In 2007-08, Indigenous 
females had the highest rate of dialysis hospitalisations, almost 15 
times that of other females, and Indigenous males were 8 times 
more likely to be hospitalised for dialysis than were other males 
[23]. For the same period, the hospitalisation rate of Indigenous 
people for the procedure of dialysis was more than 12 times that of 
non-Indigenous people [68].
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Box 3. Information about hospitalisation
Hospitalisation data are not a good reflection of the level of CKD 
in the community, but can give some indication of the impact of 
the disease as well as provide information on who is accessing 
services. Dialysis treatment is the most common reason for 
hospitalisation in Australia, with patients on dialysis needing to 
attend a hospital or satellite centre (attached to a hospital) three 
times a week for treatment [23, 49]. A person who has frequent 
admissions for the same disease (such as dialysis) is counted 
multiple times, so it is important to separate hospitalisation 
rates for dialysis from rates for other conditions [49].
In 2007-08, the most recent period for which this information is 
available, Indigenous people living in NSW, Vic, Qld, WA, SA and 
the NT were five times more likely than their non-Indigenous 
counterparts to be hospitalised for principal or additional CKD 
diagnoses other than care for dialysis [23]. Hospitalisation rates for 
CKD as both principal diagnosis and for additional diagnoses were 
between five and seven times higher for Indigenous females than 
for other females2.
Mortality
In 2004-2008, the age-standardised death rate for kidney disease 
among Indigenous people living in NSW, Qld, SA WA and the NT 
was 5.1 times the rate for their non-Indigenous counterparts3 [56]. 
The death rates for kidney disease for Indigenous people living in 
NSW, Qld, WA, SA and the NT, increased by 102% over the eight-
year period 2001-2008, compared with a 23% increase for their 
non-Indigenous counterparts [5].
Earlier data from 2001-2005 reveal that death rates involving CKD 
were especially high after the age of 25 years for both Indigenous 
males and females compared with the rates for their non-Indigenous 
counterparts [27]. In the 45-54 years age group, Indigenous males 
were 31 times more likely than non-Indigenous males to die from 
CKD. For the same age group, Indigenous females were 51 times 
more likely to die from CKD than were non-Indigenous females.
Deaths involving CKD can occur in the context of other chronic 
conditions, so published death rates for CKD underestimate its 
contribution to mortality [7, 69]. For example, a common underlying 
cause of death for Indigenous Australians living in NSW, Qld, WA, 
SA and the NT in 2003-2007 where CKD was an associated cause 
2	 These	data	refer	to	episodes	of	admitted	care,	meaning	the	same	
patient	can	potentially	have	multiple	hospitalisations	within	the	same	
period.	Consequently,	data	represents	health	service	usage	by	those	
with	CKD	rather	than	representing	the	number	or	proportion	of	people	
in	Australia	with	CKD	admitted	to	hospital.
3	 Indigenous	identification	in	deaths	data	is	considered	of	sufficient	
quality	for	reporting	only	for	NSW,	Qld,	WA,	SA	and	the	NT
(Box 4) was diabetes (28%), but for non-Indigenous Australians this 
was the equal least common underlying cause of death (8%) [7].
Box 4. Underlying and associated causes 
of death
Cause of death coding provides for classification according to 
whether a condition was an underlying or associated cause of 
death [3, 7]. This means that CKD can be coded as the underlying 
cause (i.e. either led directly to an individual’s death) or coded 
as an associated cause (i.e. contributed to the death but was not 
related to the condition causing it) [7].
Table 4. Underlying cause of death where CKD was an associated cause, 
by underlying causes and Indigenous status, NSW, Qld, WA, SA 
and NT, 2003-2007
Underlying cause of 
death (ICD-10 codes)
Indigenous Non-
Indigenous
Number Per 
cent
Number Per 
cent
Cardiovascular diseases 
(100-199)
326 30 13,816 44
Diabetes (E10-E14) 303 28 2,432 8
Neoplasms (C00-D48) 107 10 6,062 19
Respiratory diseases 
(J00-J99)
88 8 2,636 8
Other (balance) 263 24 6,634 21
Total 1,087 100 31,580 100
Source: [7].
Notes:
 1 Excludes hypertensive kidney disease.
 2 Excludes diabetic nephropathy.
 3 Excludes 323 cases where Indigenous status was not stated or 
inadequately described. 
An analysis of deaths from kidney disease for the period 2002-2005 
found that the age- standardised rate for Indigenous people living 
in remote areas was higher than the rates for those living in outer 
regional and very remote areas (7.9 per 1,000 population compared 
with 4.6 and 4.8 respectively) [70]. The higher rate for remote areas 
than for very remote areas is contrary to expectations. The authors 
raised the possibility that this could be at least partly due to a better 
social environment, increased physical activity, healthier diet and 
lower consumption of alcohol and other drugs in very remote 
areas compared with remote areas. An alternative explanation is 
that the difference in death rates could be due to selection bias; 
that is, people from very remote areas tend to move to population 
centres for better access to health services for themselves or sick 
family members.
7Review of kidney disease among Indigenous people
http://www.healthinfonet.ecu.edu.au/kidney_review
Other kidney health disorders
Glomerulonephritis
Like the broad terms ‘kidney disease’ and ‘renal disorder’, 
‘glomerulonephritis’ is a collective term that refers to a number 
of pathologies that cause inflammation of the glomerulus and 
subsequent damage to the filtration process of the kidney [38, 
43]. Of the various conditions covered by the term, acute post-
streptococcal glomerulonephritis (APSGN; see Box 5) is the most 
important contributor to high rates of chronic kidney disease and 
continues to pose a significant public health problem in developing 
countries and among Indigenous populations of the developed 
world [33, 38].
Box 5. Acute post-streptococcal 
glomerulonephritis (APSGN)
APSGN is a potentially serious, non-suppurative condition that 
occurs two to three weeks after skin or throat infection with 
some strains of group A streptococcus (GAS) bacteria [34, 71]. 
Occasionally, infections with groups C or G streptococcus may 
also cause APSGN [34]. ASPGN can cause high blood pressure, 
haematuria with reduced serum complement levels, albuminuria 
and oedema, and is often complicated with acute kidney failure 
[34, 72]. The usual period between infection and development 
of APSGN is 1-4 weeks with an average of 10 days, but this may 
be longer (3-6 weeks) after streptococcal skin infections or 
shorter (1-2 weeks) after streptococcal throat infections [73, 74].
Extent of acute post-streptococcal 
glomerulonephritis (APSGN) among 
Indigenous people
Incidence and prevalence
APSGN has been uncommon among affluent populations of 
developed countries since the mid-1900s due mainly to the 
improvements in living conditions and later because of the 
availability of antibiotic therapy and improved access to health 
care [33]. APSGN is relatively uncommon in the general Australian 
population, but poses a significant public health problem in 
tropical Australia where pyoderma, skin infections and scabies are 
endemic [34, 72, 75-80] with up to 50% of the children infested with 
scabies [52, 81, 82]. The incidence of APSGN in the NT is among the 
highest in the world with a rate in Indigenous children under 15 
years of 94 per 100,000 population reported for the period 1991 to 
2008 [34, 83]. 
Most cases of APSGN follow skin infections rather than throat 
infections because skin infections are the most pervasive problem 
[34, 72]; children aged between 12 months and 17 years are 
predominantly affected [34]. Secondary infection of scabies with 
GAS, which occurs in 50-70% of cases, is the principal cause of 
APSGN [84]. APSGN outbreaks continue to occur in northern 
Australia with a yearly peak between April and June of sporadic 
cases and small clusters; larger and more widespread outbreaks 
occur around every five years across the Top End [34, 75]. 
Results of studies on the contribution of post-streptococcal 
glomerulonephritis (PSGN) to chronic kidney disease vary, but 
recent research [14, 53, 84, 85], and previous research undertaken 
in isolated Indigenous communities experiencing outbreaks of 
APSGN in 1980 [86] and 1987 [87] suggest that a history of APSGN 
in childhood is a risk factor for subsequent kidney dysfunction [14, 
83, 88]. Findings from an early study, which used the albumin to 
creatinine ratio (a sensitive early marker of kidney damage) as its 
main outcome measure, suggest that about one-quarter of cases 
of overt albuminuria may be attributable to APSGN in childhood 
[88]. Albuminuria has since been shown to mark early chronic 
kidney disease in Aboriginal and Torres Strait Islander people [11, 
12, 14, 89-91]. Detailed consideration of the early markers of kidney 
disease is beyond the scope of this review, but current available 
data suggest that albuminuria may be a better prognostic marker 
of kidney disease than a low estimated glomerular filtration rate, 
which may be inaccurate in the Indigenous population based on 
comparisons made between an urban Indigenous population and 
those from the general Australian adult population [91]. 
APSGN outbreaks in Indigenous communities
Outbreak investigations and surveillance studies provide some 
indication of the extent of APSGN within Indigenous communities 
[72, 73, 75, 76, 79, 83, 92] but methodological difficulties 
surrounding the identification of cases and the estimation of rates 
suggest that the true incidence of APSGN is likely to be higher 
than these estimates [83, 93]. Identification issues include: lack of 
a standardised case definition; limitations and logistical difficulties 
associated with diagnosing the condition in isolated communities 
[33, 93]; and the high proportion of sub-clinical cases of disease [33, 
34].
In the last decade, Indigenous children with skin infections during 
APSGN outbreaks were five times more at risk to develop ASPGN 
than were their non-Indigenous counterparts [80]. In 2008, an 
outbreak was recorded in the NT where a 5 year old child first 
presented with GAS and subsequently APSGN. In the following 
two days, two more cases were found. A complete screening of 
school-aged children (under 15 years) revealed that 36% of the 
screened children presented with skin sores and 12.5% presented 
with scabies, but no other case of APSGN was found [75]. In 2007, 
prospective surveillance investigating the epidemiology of GAS 
in three remote Aboriginal communities in the NT found that 
inadequate health awareness, crowded household conditions and 
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population mobility were important driving forces behind GAS 
dissemination, with household acquisition commonly transmitted 
via 5-9 year olds [94, 95]. Responses to APSGN outbreaks have seen 
improvements in screening, but Indigenous communities in the 
NT continue to experience epidemics of APSGN around every 5-7 
years with the last known outbreak occurring in 2008 [73].
Numerous outbreaks in the NT have received rigorous investigation 
and sound documentation since the early 1980s [73, 75, 76, 79, 80, 
83, 86, 87, 92, 95-98], but, until more recently, epidemics have been 
less frequently documented in other areas of northern Australia. 
Prior to 1993, not a single epidemic had been reported in far north 
Qld for almost 20 years, but 58 cases (10% of all children screened) 
were diagnosed among Indigenous children from three remote 
communities in that year [96] and in 2006, an outbreak of ASPGN 
was recorded in the Lockhart River community in far north Qld [72]. 
From over 87 children screened, 46% were infected by scabies. In 
a four month period, 11 cases of ASPGN were confirmed. More 
recently, a retrospective review of the clinical records of all cases of 
invasive group A streptococcal (iGAS) disease notified to Qld health 
authorities during the 5-year period 2004-2009 revealed that 
there was marked underreporting in Qld [77]. Even with reports 
across different districts differing markedly and a large number of 
isolates not reported, rates of invasive disease were higher in the 
Indigenous population than in the non-Indigenous population. As 
revealed by previous research, rates of iGAS were especially high 
in infants, with the incidence 10 times higher among Indigenous 
infants than among their non-Indigenous counterparts (123 per 
100,000 compared with 12 per 100,000). 
Mortality and morbidity 
The clinical course of APSGN has been described usually as mild, 
with complete recovery within days or weeks [34, 86, 88, 99]. The 
long-term outlook has generally been regarded as excellent [88], 
but, despite the apparently benign clinical profile, APSGN has also 
been associated with significant morbidity, hospitalisation and 
occasional mortality [93, 97]. Recent information on mortality and 
morbidity associated with APSGN are not available, but it is known 
that APSGN may occasionally cause acute kidney failure and that 
hypertension is the most frequent major complication [34].
Earlier research investigating the morbidity associated with APSGN 
in far north Qld reported that of 100 identified cases (of which 
96 were Indigenous), 72 were admitted to hospital where they 
remained an average of 8.5 days (range: 3-30 days) [93, 97]. Major 
complications included severe hypertension (40 per cent of all 
cases), acute kidney failure (18 per cent of all cases), fluid overload/
pulmonary oedema (12 per cent of all cases) and bacteraemia 
(6 per cent of all cases). One child died, another developed 
pneumococcal pericarditis and a purulent effusion and required 
surgery, and a young pregnant woman underwent dialysis to 
manage acute kidney failure - all were Indigenous [97].
Factors contributing to high levels of APSGN in 
northern Australia
Humid climatic conditions in tropical northern Australia, the 
ubiquity of scabies and skin sores, and the relatively poor social 
and economic circumstances of many Indigenous people as 
identified elsewhere in this review, all contribute to the high rates 
of APSGN [34, 52, 81, 82] [38, 79, 100]. In communities with high 
levels of scabies and skin sores, new strains spread very quickly 
with transmission facilitated by overcrowded living conditions and 
infrastructure problems in many remote communities [78, 82]. The 
ease with which new strains of GAS are transmitted in families and 
communities is reflected in the rapid spread of APSGN [34]. Limited 
access to medical care, poor personal hygiene and inadequate 
environmental sanitation are also major contributing factors to the 
spread of the disease [34, 78, 82].
Prevention and management of ASPGN
There is no vaccine for GAS and no simple treatment for APSGN. 
In the absence of interventions, new cases can continue for 
several months [34]. Attempts to control APSGN outbreaks (Box 
6) in Indigenous communities have frequently involved trying to 
stop the transmission of the bacteria by mass administration of 
parenteral penicillin to all children with any sign of skin sores [34, 
72, 92, 96, 99], and sometimes regardless of whether they present 
with skin sores [76, 79]. The targeted treatment of children with 
skin sores and household contacts has shown to be an effective 
intervention with the need for fewer injections (the injection 
is painful and reactions may occur) and a less labour-intensive 
response (that is correspondingly less likely to compromise routine 
services or miss high-risk children) [79, 99]. Past trials employing 
more sensitive outbreak case definitions (‘sub-clinical’ cases now 
referred to as ‘probable cases’ and ‘clinical cases’ referred to as 
‘possible cases’) have also resulted in an improvement in the 
screening of high risk communities [79].
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Box 6. Current guidelines for the control 
of APSGN
Following the recording of an outbreak of APSGN, communities 
are advised to follow the guidelines for its control provided 
by the NT Centre for Disease Control (CDC) [34]. Currently, the 
guidelines define a community outbreak as either:
•	 two unrelated cases, either probable or confirmed that 
meet the clinical definition of APSGN (without laboratory 
confirmation) with onset within a week or each other, or
•	 one confirmed case and two probable cases in one month of 
each other that are not epidemiologically linked as a family, 
household or close contact.
Guidelines include community education and screening of all 
children up to the age of 15 years for skin sores, scabies and 
oedema. Management of infection currently involves hospital 
admission for major complications, coupled with the use 
of antibiotics to inhibit spread of the disease. If oedema is 
present, then the child is strongly advised to be assessed for 
manifestations of APSGN [34, 52].
A recent community screen in April 2011 reported that 57% of 
targeted children were screened [73]. The successful access to 
the community largely resulted from the initial groundwork 
undertaken by the local health service, which facilitated 
community engagement beforehand as well as the expertise of the 
local Aboriginal health workers in identifying children and families. 
The use of ‘high quality’ rewards (in the case of this screening it 
was a plastic Sticky Hand developed by the Environmental Health 
Program) to attract more children to screening and treatment was 
also noted as a successful strategy to assist with the engagement 
of children about to receive injections.
In summary, good primary health care has been recognised as vital 
in the recognition and referral of APSGN, as early recognition of 
outbreaks and timely treatment is crucial in preventing the spread 
of GAS in the community and possible irreversible loss of kidney 
function [34, 74]. The coexistence of high rates of GAS infections, 
APSGN and ESKD in northern Australia has raised the question of 
whether childhood APSGN could be linked with chronic kidney 
disease in later life [53, 75, 85]. With the aetiological link between 
scabies, streptococcal skin infections and outbreaks of APSGN well 
recognised [34, 52, 101], interventions for sustainable long-term 
improvements in skin health and the integration of environmental 
health, housing and hygiene programs with such interventions, are 
an essential part of the prevention, management and treatment of 
APSGN outbreaks [75, 79, 101-104]. An improvement in education, 
sanitation, and access to treatment is also a crucial step toward 
decreasing the incidence of glomerular disease [9, 38]. Secondary 
and tertiary prevention depends on improved surveillance, 
screening to identify cases, and penicillin prophylaxis to eradicate 
streptococcal carriage and stem the spread of epidemic disease 
[52, 96]. Prevention at this level will not only reduce rates of APSGN 
but may also contribute to a reduction in the incidence of ESKD 
[51, 52, 88].
Disorders of the urinary tract
Disorders of the urinary tract (specifically disorders of the bladder, 
ureters and urethra) generally present as clinically mild cases, 
but they have the potential to cause considerable morbidity, and 
may, on occasion, lead to severe kidney disease, including ESKD 
[38, 39]. The potentially serious consequences associated with 
urinary tract disorders, coupled with their prevalence (particularly 
among women), highlight the public health significance of these 
conditions. Urinary tract infections (UTIs) (Box 7) are generally 
bacterial in origin, but, fungi, parasites and adenoviruses may also 
cause infection [39].
Box 7. Urinary tract infections (UTIs)
Most UTIs occur in the lower urinary tract as cystitis (in the 
bladder) and urethritis (in the urethra) [39, 103]. Pyelonephritis, 
an upper UTI, is very serious as it may damage the kidneys. 
The urinary tract is normally free of bacteria and other micro-
organisms, but these organisms can get into the bladder by 
coming up the urethra from the outside; sometimes they 
can enter from the kidneys or bloodstream [103]. Once in the 
bladder, bacteria can multiply very rapidly in warm urine. A 
UTI may be present despite few physical symptoms, but lower 
UTIs are typically associated with frequent, painful urination, 
and tenderness in the lower pelvic area [39]. Upper UTIs are 
associated with a range of clinical features, most commonly 
fever, back or loin pain, and chills [103]. Single episodes of UTI 
rarely have serious consequences, but recurrent or persistent 
infections may cause kidney damage when coupled with 
conditions such as diabetes [38]. Lower UTIs are easily treated, 
generally by a single dose or short course of antibiotics [39, 103]. 
Upper UTIs usually require hospitalisation and administration of 
intravenous antibiotics. Antibiotics may also be administered to 
prevent recurrent infection.
UTIs are one of the most common reasons for people visiting 
a doctor about an infection [39]. Females are much more likely 
than males to contract UTIs, and other risk factors include age 
and sexual activity [38, 105]. In Australia, about one in three adult 
women and one in 20 men will have a UTI in their lifetime. Women 
tend to be more susceptible to UTIs for several reasons, including 
the length of their urethra; the urethra is much shorter in females 
than in males, making it easier for microorganisms to travel to 
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the bladder. Other factors include changes in hormonal levels 
(women are more likely to get an infection during certain times 
in their menstrual cycle, particularly just before a period and are 
also more susceptible during pregnancy). In women, the tissues 
of the urethra and bladder become thinner and drier with age, 
as well as after menopause or a hysterectomy: this also increases 
susceptibility to UTI [39, 103].
Extent of UTIs among Indigenous people
The health impact of diseases of the urinary tract upon Indigenous 
people has received very little attention in recent years, but 
information from the 1980s suggests that the pattern of UTI 
exhibited among Indigenous people tends to differ from that 
observed among non-Indigenous people [105]. Epidemiological 
and anecdotal evidence from the 1980s indicates that UTIs were 
particularly common among Indigenous people [105, 106]. A 
hospital-based study in Darwin found that Indigenous men 
and women had higher rates overall of UTI than did their non-
Indigenous counterparts, but age-specific rates were greater 
among non-Indigenous people after the age of 60 years [105]. With 
the exception of children in their first year of life, UTIs occurred far 
more frequently among Indigenous females, with consistently 
high rates of infection until around 60 years of age. Indigenous 
males, on the other hand, were at greatest risk during infancy. 
Unfortunately, easily treated UTIs often remained undetected, 
particularly in Indigenous children, which increased the individual’s 
risk of developing more serious kidney disease [106]. Inadequate 
living conditions and poor environmental standards are thought to 
contribute to the high levels of UTI observed in some Indigenous 
communities [38, 106].
Other data reveal that Indigenous women are more than twice as 
likely as non-Indigenous women to have a UTI during pregnancy 
[107, 108]. A retrospective audit of medical records from rural 
and remote primary health care clinics in the NT of 268 pregnant 
women who gave birth in 2002 or 2003 revealed that 75% had 
at least one abnormal urinalysis during pregnancy (620 episodes 
were recorded overall) [107]. This is consistent with findings from 
earlier research that found almost 30% of Indigenous women 
sampled had a UTI during pregnancy, and 11% had an infection 
at the time of delivery [109]. Evidence from these studies suggests 
that screening, treatment and follow-up of UTIs among Indigenous 
people was often inadequate [106-109]. The occurrence of 
pyelonephritis (acute UTI that has reached the pelvis of the kidney) 
in women who had non-treated asymptomatic bacteriuria during 
pregnancy highlights the importance of screening, particularly for 
women living in rural and remote Indigenous communities.
Urolithiasis (kidney stones)
Urolithiasis refers to the formation of one or more pebble-like 
masses (commonly referred to as calculi or stones) in the kidney 
or urinary tract [31, 32]. It is not a common public health problem 
within affluent populations in developed countries, but its 
prevalence and unusual presentation among some Indigenous 
children justifies its coverage here [40].
Extent of urolithiasis among Indigenous people
Very little attention has been directed at urolithiasis among 
Indigenous people since the 1990s, but the presence of a unique 
pattern among Indigenous children has been confirmed recently 
[40]. The findings of this study of Indigenous children presenting 
to the Darwin Hospital were very similar to those reported in the 
1980s and 1990s [110-116].
The Darwin study found that Indigenous children living in remote 
areas of tropical and desert Australia have an unusual pattern of 
kidney stones [40]. Stones form early in life: the median age of 
presentation was 24 months with some stones recognised as 
early as 8 months of age. This pattern contrasts with that reported 
among non-Indigenous people and other populations of the 
developed world where the incidence is much higher among 
adults than children [40, 110, 115].
The recent research [40] is consistent with the reports from the 
1980s and 1990s: Indigenous children with urolithiasis tend 
to come from desert regions of Australia, are more likely to be 
male, and are frequently less than 3 years of age [110-113, 115]. 
Urolithiasis is rare among Indigenous children living in urban 
areas [40]. Children with stones commonly present with, or have 
a history of, failure to thrive, UTI, and/or recurrent infectious 
disease (particularly diarrhoea) [40, 110-113, 115]. The stones 
found in Indigenous children are rarely associated with anatomical 
or metabolic disorders and are commonly located in the upper 
urinary tract [110, 111, 113, 115]. They are composed primarily 
of uric acid, and oxalate [110-113], similar to the ‘endemic’ stones 
typically found in paediatric populations from developing regions 
of the world where the disorder is prevalent [110]. 
The formation of calculi in non-Indigenous Australian children is 
uncommon [40, 110, 112]. When urolithiasis does occur in non-
Indigenous children, it presents at a later age (usually mid to late 
childhood) and is generally attributable to a malformation of the 
urinary tract or a metabolic disorder [110, 112]. A comprehensive 
review of patient records collected between 1972 and 1986 from 
the major paediatric referral hospital in WA reported that the 
number of Indigenous children presenting with urolithiasis was 
more than double that of non-Indigenous children [110]. A review 
of patients with urinary tract calculi admitted to the Urology Unit of 
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the Adelaide Children’s Hospital between 1978 and 1987 estimated 
that 0.34% of Indigenous children under 10 years of age (based on 
1981 census figures) suffered from the disease [112].
Factors contributing to urolithiasis among 
Indigenous people
Acidic stones are produced when there is a loss of alkaline bowel 
content (as a result of diarrhoea for example) [40]. The high rates of 
urolithiasis observed among some Indigenous children have been 
attributed to dietary factors, dehydration, endemic diarrhoea, 
recurrent infectious disease [40, 110-115], hot, dry environmental 
conditions [110, 111] and poor water quality [114]. These risk factors 
are intimately related to the familiar socioeconomic risk factors 
that underlie the high burden of disease suffered by Indigenous 
people generally.
Management and treatment of urolithiasis
Some stones appear to resolve spontaneously, but others might 
require surgical removal to avoid the risk of kidney damage 
[40]. The specific causes of kidney stones should be treated 
appropriately, but general treatment includes increased fluid 
intake (i.e. drinking water which is especially important for children 
during the weaning period and in for those warm climates), limited 
daily salt intake, moderate animal protein intake and medical 
treatment with alkali and thiazides (including sodium bicarbonate 
or potassium citrate [38, 40]. Attention must be directed to the 
long-term public health implications and the need for preventive 
measures [112]. Housing, water and waste disposal systems are 
inadequate in many Indigenous communities and increase the 
risk of urolithiasis. Improvements in environmental conditions, 
specifically the provision of adequate drinking water and the 
eradication of poor living conditions, are therefore essential to 
reduce the incidence of kidney stones [40, 114].
Management and treatment of 
CKD and ESKD
Kidney disease is expensive to treat and has a marked impact 
on the quality of life of those who suffer from the disease and of 
those who care for them [8, 27]. Medical intervention is necessary 
to prevent deaths among individuals with CKD and ESKD. The 
current treatment option for ESKD involves KRT including dialysis 
(either haemodialysis (HD) or peritoneal dialysis (PD) (Box 8) 
and transplantation [9, 29]. The aim of treatment for CKD (prior 
to reaching ESKD) is to delay progression of the disease. If CKD 
progresses to ESKD, KRT becomes necessary with the aim of 
providing ongoing quality and quantity of life rather than focusing 
the prevention of further deterioration of kidney function [7, 9]. 
KRT cannot cure failing kidneys, but dialysis can enable survival. A 
further aim of treatment is to prevent added complications, such as 
cardiovascular issues [28, 29]. Therefore, management of CKD also 
involves lifestyle modifications including: cessation of smoking; 
maintaining BMI below or equal to 25 kg/m2; engagement in 
regular physical activity; reducing alcohol and drug consumption; 
and maintaining a low salt diet [29].
Box 8. Dialysis: haemodialysis (HD) and 
peritoneal dialysis (PD)
Regular dialysis mechanically filters the blood to help maintain 
the functions normally performed by the kidneys [7, 9]. There 
are two possible dialysis treatment options; haemodialysis (HD) 
and peritoneal dialysis (PD) [3, 7, 117]. Both treatment options 
aim to replace part of the (damaged) kidney’s function and both 
can be conducted from home and by the patient themselves 
[7, 117].
Haemodialysis (HD)
In HD, blood is diverted from the body to a dialysis machine 
where it is filtered before being returned to the body [7, 9]. As 
HD requires a costly machine to assist in the filtration of fluids 
outside the body [55], it is conducted at various locations, 
including hospital or dialysis units (located in tertiary hospitals), 
satellite centres (facilities linked with a tertiary centre renal 
unit) or managed carefully in the home [7, 118]. The limited 
availability of such services outside of population centres, 
means that many Indigenous people are often forced to stay 
away from their land and families for long periods of time [55, 
118-120] and can mean that they die away from their people. 
Peritoneal dialysis (PD)
In PD, the dialysis solution, containing a type of sugar that draws 
waste products and extra fluid out of the blood, is pumped into 
the abdomen and the blood filtered through the peritoneal 
membrane [9, 55]. After a few hours the used solution containing 
waste and extra fluid is drained out of the body and replaced 
with fresh solution. The exchange takes about 30-45 minutes 
and can be undergone manually but requires dialysis exchanges 
4-5 times daily; known as continuous ambulatory peritoneal 
dialysis (CAPD), or through the use of a machine which controls 
the timing of fluid exchanges while the patient sleeps; known 
as automated peritoneal dialysis (APD) [7, 55, 118]. Most people 
use PD at home, given its portability and convenience [7, 118]. 
Both forms of treatment offer an alternative for people with 
CKD living in remote areas as it allows more independence and 
greater opportunity to return home more quickly [3, 121].
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Extent of dialysis among Indigenous 
people
A total of 187 Indigenous people commenced dialysis in Australia 
during 2009, a decrease from 249 in 2008 and 237 in 2007 [4]. In 
2009, 1,174 prevalent dialysis patients in Australia were Indigenous; 
the level for Indigenous people was nearly five times that of their 
non-Indigenous counterparts (2,220 compared with 473 per 
1,000,000 population) [Derived from 4]. 
Based on information about hospitalisation, ‘care involving 
dialysis’ was most common for Indigenous people living in very 
remote areas (154 hospital separations per 1,000 population) 
[68]. Similarly, hospital separations relating to renal failure by 
socio-economic quintiles4 revealed that the ‘most disadvantaged’ 
quintile (representing the areas containing the 20% of the 
population with the least advantage/most disadvantage) had the 
highest separation rates dialysis. The residence in very remote 
areas of many Indigenous people requiring dialysis has important 
implications for how appropriate services are delivered.
Issues associated with relocation to undertake 
dialysis
When dialysis facilities are not available near to where the 
Indigenous patient lives, they are forced to move to regional 
centres or major cities to undertake dialysis. The lack of treatment 
available in remote areas and the limited availability of transplant 
facilities create geographical barriers to treatment with 78% of 
patients in remote areas having to relocate, compared with 39% 
of those who live in rural areas and 15% of urban Indigenous ESKD 
patients [6]. In recent years, research has revealed the significant 
biological, psychological, social and economic consequences to 
the forced relocation of Indigenous patients [122, 123].
A study of Indigenous renal patients moving to Alice Springs from 
remote central Australian communities reported the socio-cultural 
alienation as extreme, debilitating and ultimately life threatening 
[124]. Recent research in WA reported similar findings for relocated 
Indigenous renal patients in that state [123]. The loneliness 
resulting from removal from family and land, including a sense of 
loss and disempowerment were considered worse than the illness 
(CKD) itself. Added to the stress of not being able to attend cultural 
events and obligations, the geographical isolation associated with 
treatment options often discourages Indigenous people from 
4	 The	Index	of	Relative	Advantage	and	Disadvantage	is	one	of	the	ABS’s	
Socio-Economic	Indexes	For	Areas	(SEIFA)	2006,	generated	using	a	
combination	of	2006	Census	data	(i.e.	income,	education	and	dwelling	
size).	Composite	scores	are	indicative	of	the	collective	socioeconomic	
status	of	the	people	living	in	an	area,	with	reference	to	the	situation	
and	standards	applying	to	the	wider	community	at	a	given	point	in	time	
[68]
seeking treatment [6, 123]. The impact of such issues is further 
highlighted by data reporting social causes as the second most 
important cause of death of Aboriginal and Torres Strait Islander 
people on dialysis (24%), after cardiac events (37%) [4].
In a bid to address poor treatment outcomes associated with 
relocation, efforts have been made to deliver self-care PD and 
HD dialysis services close to, or in, the home [125]. This means 
that Indigenous people remain in their own communities, with 
their own family and social supports, and the costs of re-housing 
and supporting relocated dialysis patients are avoided. However, 
challenges facing home HD in remote communities include 
being able to retain suitable dialysis partners/carers due to their 
requirements for attendance at cultural duties, suitable housing, 
changing social circumstances and communication problems (such 
as language barriers) [118, 126]. In Queensland, three health zones 
have developed Renal Service Plans in recognition of Indigenous 
people as a priority population and in acknowledgement that many 
rural/remote areas of the state do not have ready access to hospital 
renal units or satellite units [127]. These plans include specific 
strategies to address kidney disease including health promotion, 
early detection, clinic management, kidney replacement services, 
workforce management and information support actions all 
specifically tailored to the needs of Indigenous people. Examples 
include the opening of the Mt Isa satellite service and the multi-
user, self-care dialysis strategy established in the Toowoomba Renal 
Service. Satellite dialysis facilities are becoming more common in 
remote areas, but, in view of the low population density in many 
areas, access to treatment for people with ESKD is still an issue 
that requires dramatic changes in living circumstances [69, 128]. 
Given ESKD relocation and treatment issues, it is considered good 
practice to allocate patients to the closest treatment facilities and 
to develop socio-culturally sensitive services for the specific needs 
of Indigenous patients.
In the search for alternative dialysis treatments, research has 
examined the use of Automated Wearable Artificial Kidneys (AWAK) 
[129]. Potential advantages proposed for this type of device include 
steady-state metabolic and fluid control, continuous regeneration 
of spent dialysate and the round-the-clock functionality of the 
device (mimicking the natural kidney). Such outcomes would 
allow patients to stay at home for their treatment and minimise 
interruption to their everyday activities. Despite AWAK’s potential 
to affect the wellbeing of CKD sufferers, especially Indigenous 
people in rural and remote areas, this type of treatment is still in a 
speculative stage of development. 
Extent of HD among Indigenous people
Conducted in urban or regional clinics and hospitals, HD is the 
most common form of dialysis treatment for Indigenous people 
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with ESKD [4, 27, 55, 118, 120]. In 2009, HD accounted for 81% 
of the new cases of Indigenous people commencing dialysis [4, 
37] and for the period 2007-08, hospitalisation data showed that 
Indigenous people were undergoing HD at 12.1 times the rate 
of non-Indigenous people5 [68]. In the same year, one in three 
hospital procedures for Indigenous peoples were for HD with 
recorded hospital separations higher in more remote areas. 
A recent study comparing clinical outcomes and mortality rates 
of Indigenous people of Kimberley origin receiving HD treatment 
with other subsets of Indigenous HD patients and non-Indigenous 
Australians, revealed for the first time, similar mortality rates [130]. 
As a response to the new model of care for Kimberley patients 
undergoing HD in 2002, the study investigated outcomes for 
patients of Kimberley origin between January 2003 and December 
2007, including patients receiving any form of KRT in any Australian 
location for that time period. An overall average of 70% of patients 
of Kimberley origin received HD treatment mainly provided by 
the Kimberley Satellite Dialysis Centre (KSDC), operated by an 
Aboriginal Community Controlled Health Service (ACCHS). The 
treatment was delivered at KSDC, at home in communities across 
the Kimberley, and at Derby Aboriginal Health Service. The study 
found that Indigenous people from the remote Kimberly region 
received HD treatment as good as elsewhere in the country. 
The authors felt that the excellent adherence of patients to care 
could be attributed to the delivery of quality services in culturally 
appropriate settings.
Extent of PD among Indigenous people
In 2009, the number of Indigenous people commencing peritoneal 
dialysis (PD) (35 patients) in Australia was less than in the previous 
two years [4]. By reducing the risks associated with relocation for 
HD, there are potential advantages of PD. However, as PD requires 
the patient to replace the dialysate bag several times a day with 
failure to change the bag resulting in life- threatening conditions, 
this places more responsibility on the patient to ensure correct 
management of the treatment [55]. Research has shown the correct 
management of PD treatment is impeded by various factors, such 
as infections and/or problems with the peritoneal dialysis catheter, 
home environment and child responsibility, constipation and 
treatment simply not suiting the individual [55]. Some anecdotal 
evidence also indicates that issues associated with changing the 
dialysate bag at home, such as facility issues with power and water, 
often leads to Indigenous people making the choice to undertake 
HD away from home. As previously discussed, this can create stress 
associated with having to relocate [123]. 
5	 Data	do	not	represent	the	number	or	proportion	of	people	in	Australia	
with	CKD	admitted	to	hospital	but	rather	health	service	usage	by	those	
with	CKD.
General issues associated with HD and PD
The multifaceted negative implications of HD and PD for Indigenous 
patients also reflect the differences between medical culture and 
that of Indigenous communities. Miscommunication between 
Indigenous patients and health care workers can occur because 
of differences in cultural and social beliefs on health, and in the 
understanding of the patient’s situation and ongoing treatment 
[43, 131, 132]. Such miscommunication is exacerbated for those 
Indigenous patients for whom English is a second language. 
Appropriate information and the associated understanding of 
the patient and their family are key for the patient – and their 
family and community – to make the important decisions about 
treatment choice [124, 131, 133]. 
Transplantation
Transplantation involves the implantation into a patient with ESKD 
of a kidney from either a living or recently deceased donor [7, 9]. 
A recent systematic review of 110 international studies including 
a total of 1,961,904 participants with kidney failure revealed that 
transplantation was associated with substantial reductions in 
the risk of mortality and cardiovascular events [134]. It was also 
associated with clinically relevant improvements in quality of 
life, which improved further over time compared with treatment 
with different dialysis modalities. These findings confirm that 
kidney transplantation, when feasible, is the preferred therapeutic 
option for the management of CKD for patients and by health-
care professionals [134, 135]. Earlier studies revealed that the 
annual death rate of an age-matched population maintained by 
transplantation was reduced by about 80% beyond the first year 
compared with those remaining on dialysis [135, 136]. The use of 
kidneys with no human leucocytes antigen (HLA) mismatches was 
associated with superior outcomes, but, unfortunately, completely 
matched kidneys account for a very small proportion of organs 
transplanted [137].
Extent of transplantation among Indigenous 
people
Transplantation is the optimal form of treatment for most ESKD 
patients, but there is a pronounced disparity between Indigenous 
people and non-Indigenous Australians for this treatment [117]. 
At the end of 2008, a far greater proportion of Indigenous people 
than non-Indigenous Australians were reliant on dialysis for KRT: 
only 12% of Indigenous people were living with a functioning 
transplant compared with 45% of other Australians6 [5]. Indigenous 
6	 Due	to	data	quality	issues	relating	to	Indigenous	identification,	hospital	
data	by	Indigenous	status	was	restricted	to	hospitals	in	NSW,	Vic,	
Qld,	WA	SA	and	public	hospitals	in	the	NT	and	hospitalisations	where	
Indigenous	status	was	missing	or	unknown	were	amalgamated	with	
those	identifying	as	non-Indigenous	or	‘other’	Australians.	
14
Austr AliAn indigenous HeAltHReviews  no.11
Copyright © 2013 Australian Indigenous HealthInfoNet 
patients are both less likely than other Australians to receive a 
transplant and less likely to be wait-listed for a transplant [4, 117, 
137]. Indigenous people receive transplants at approximately 
one-third the rate of other patients and those who do receive 
transplants wait longer for them [4]. 
In the four-year period 2006-2009, 2.1% of Indigenous people 
needing KRT received a transplant, compared with almost 11% of 
non-Indigenous people [Derived from 4]. For the same period, only 
4% of all people on the waiting list were identified as Indigenous. 
Only 100 new transplant operations involved Indigenous 
recipients compared with 1,741 for non-Indigenous recipients. In 
most Australian states, the average wait for a kidney transplant 
from a deceased donor is about 4 years, and for some patients the 
wait is much longer [135]. Those Indigenous people who undergo 
transplantation usually need to travel large distances to reach 
medical centres [6, 138].
Factors associated with access to kidney 
transplantation
Research investigating the reasons for the disparity between 
Indigenous ESKD patients and non-Indigenous patients receiving 
transplants (Box 9) reveals some key barriers to the accessibility 
of treatment [117]. System factors included: reduced likelihood 
of referral for transplant evaluation; failure to complete the 
comprehensive set of investigations required; and communication 
and education limitations. Individual factors included: greater 
likelihood of human leucocyte antigen (HLA) incompatibility; fear 
of their health status; refusal to leave land and community; higher 
rates of co-morbidities affecting acceptability for transplantation; 
and lower compliance to medical treatment as a result of 
communication problems and misunderstandings.
Box 9. Organ allocation in Australia
The allocation of organs, including kidneys, is a complex 
process that depends on a range of factors including medical 
need, urgency and the capacity of the recipient to benefit from 
the transplantation [139]. In Australia, allocation systems are 
underpinned by the principles of utility, equity and fairness. 
Kidneys matched by blood group and tissue compatibility are 
offered to the best suited recipient, regardless of where they 
live. There are only a few kidneys available for transplantation, 
so only patients deemed medically or otherwise appropriate 
are able to receive transplants. Patients are educated about 
the process to ensure informed decision making before being 
placed on the waiting list. When a donor organ becomes 
available or is identified, transplantation can take place [117].
A palliative care approach to the management and treatment of 
CKD and ESKD
Practices are being developed throughout Australia that contribute 
to the improvement of care, prevention and culturally appropriate 
management of CKD and ESKD [119, 125, 140-147]. Without 
the option of transplantation, dialysis is the only final stage 
treatment available for ESKD and, as such, it has the potential to be 
systematically coupled with palliative care units. For example; the 
Improving care for people with advanced chronic kidney disease: 
I’m OK project allocates Indigenous patients to a care coordinator 
who liaises with the different health professionals that the person 
sees [119]. The goal of the project is to reduce communication 
problems and enable close-to-home access to specialist health 
care in regional Aboriginal community controlled health services in 
the Northern Territory. The initiative offers a coordinated approach 
and contributes to the creation of strong links between the many 
different health staff who provide care to people with advanced 
CKD. The four-year long Palliative care for renal clients living in 
a remote setting project focuses on raising awareness of the 
palliative approach of the kidney health workforce and examines 
the palliative needs of clients with CKD [143]. The project aims to 
produce health resources and guidelines to accompany Indigenous 
renal patients through the end of their lives by providing support 
to make end-of-life decisions while also providing opportunity for 
health worker staff to embrace the palliative approach to care.
Prevention of ESKD
Kidney disease clearly has major medical and social implications 
for Indigenous people. The negative social consequences that 
accompany treatment and the high cost of tertiary level medical 
care illustrates the need for a comprehensive approach that 
addresses both the medical and socioeconomic dimensions of this 
growing problem [55, 128].
Primary prevention of the social and economic conditions that 
underlie much of the Indigenous kidney health burden is a 
fundamental priority [53, 54]. Secondary and tertiary measures, 
such as screening and pharmacological interventions, also promise 
to reduce the risk of serious kidney disease [148]. Screening 
for kidney disease has for some time been accomplished with 
simple, cheap and reliable techniques [61, 149]. Such screening 
instruments may be readily incorporated within existing chronic 
disease screening protocols and coupled with interventions to 
modify the disease process [148].
An early example of a systematic treatment program implemented 
in the Tiwi Islands (off the coast of the NT) offering primary, 
secondary and tertiary prevention measures was designed to 
intervene in the disease process before individuals progress to 
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ESKD. The program focused on vigorous blood pressure control 
and better metabolic management for people with diabetes and 
kidney disease, or with diabetes and high blood pressure and 
centred on the use of the long-acting angiotensin converting 
enzyme inhibitor, (ACEi) perindopril, an anti-hypertensive 
with cardiovascular and renal protective effects [150]. An early 
evaluation of the health outcomes of the program indicated that it 
had: slowed the progression of kidney disease; postponed kidney 
failure; reduced premature death; averted much cardiovascular 
morbidity; and diminished associated health care costs [21, 151]. 
Progression to end-stage kidney failure had been reduced by one-
half and there had also been a reduction in deaths from natural 
causes. The pattern of ESKD in the community had been reversed, 
with previously increasing rates of ESKD and natural death reduced 
[151].
The success of the program was attributed to a strong sense of 
community involvement and a partnership approach between the 
health workforce delivering the program and the community [152]. 
Specific facets of the program thought to have contributed to its 
success include:
•	 maximum involvement of local workers
•	 a community-based rather than clinic-based focus
•	 a collaborative, non-authoritarian approach
•	 involving participants in their own testing
•	 personalising health goals
•	 providing information not directives.
The program demonstrated that kidney disease can be easily 
diagnosed and its progression dramatically altered by available 
interventions [153]. It also showed that Indigenous people are 
interested in health issues and receptive to health messages; their 
willingness to participate enthusiastically and effectively in the 
long-term management of chronic disease led to demonstrable 
improvements in their kidney health [151]. Finally, the Tiwi model 
has shown that huge savings, in terms of both premature death 
and cost, are achievable if investments are made in community-
based strategies for kidney disease [150]. It is estimated that the 
Tiwi program saved between $700,000 and $3.1 million in dialysis 
costs alone in its first three years of operation [153].
The need for comprehensive health care
In recent years, there has been significant research into the causes, 
consequences and management of ESKD in the Indigenous 
population [6, 21, 54, 55, 59, 60, 131, 151, 154-157]. A growing body 
of evidence demonstrates that some progress has been made 
[57], but it highlights, too, remaining gaps in the current health 
care approach. Consideration of the evidence as a whole provides 
guidance for the way forward, primarily indicating that Indigenous 
renal patients require, and deserve, effective, acceptable treatment. 
The current emphasis on complex, expensive, often problematic, 
hospital-based treatment should be balanced with comprehensive, 
community-based, preventive action to minimise the underlying 
causes of the problem [21, 55, 59, 60, 148].
The responsibility for reducing disparities in treatment rests 
primarily with the health care system and its providers [30, 131, 
158, 159]. This will require system-level changes, such as adequate 
funding for primary care, an adequate Indigenous health workforce, 
development of shared understandings about CKD, the use of 
high-quality and culturally appropriate educational resources, and 
improvements in the interface between primary care and specialist 
services. Prevention of the socioeconomic antecedents of kidney 
disease is inherent in such an approach, which calls for:
•	 sustained improvements in living and environmental conditions, 
education, infrastructure and health service [50, 59, 61]
•	 implementation of integrated, effective and well-resourced 
primary health care programs [21, 59, 69]
•	 primary health care measures to improve diet, control blood 
pressure and infections, maintain healthy adult weight, and to 
increase birth weight [30, 50, 59, 61]
•	 systematic screening for early and established kidney disease 
[30, 50, 60, 61, 160, 161]
•	 pharmacological intervention programs to slow disease 
development [38, 60].
Evaluation is also a necessary component of any health program, 
and local ownership and management of health strategies for 
the Indigenous population is vitally important [55, 148, 162]. The 
added advantage of comprehensive action is that it will reduce 
not just kidney disease, but also other chronic and communicable 
conditions that underlie the much higher levels of mortality 
experienced by the Indigenous population [30, 161, 162]. It is 
within the capabilities of integrated socioeconomic and public 
health initiatives to quickly reduce kidney disease risk, and modify 
the existing disease profile, with potential savings in morbidity, 
mortality and health care costs [57, 162].
Policies and strategies to 
improve kidney health
In Australia, the prevention and management of CKD and related 
kidney health issues is addressed more broadly under the banner 
of chronic diseases [163] and by way of strategies identifying areas 
for improvement in all aspects of CKD [69].
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National strategies addressing CKD
The National chronic disease strategy (NCDS), released in 2006, 
includes information on CKD under the umbrella of chronic 
diseases [163]. The NCDS takes a holistic approach towards chronic 
diseases as these conditions often occur at the same time and 
their risk factors are similar. The strategy aims to better coordinate 
and manage chronic illnesses from prevention to palliation [163, 
164]. Further to this, the National chronic kidney disease strategy 
(NCKDS), proposed in 2006 by Kidney Health Australia, was released 
in response to the increasing burden of CKD in the Australian 
community [69]. Given the commonalities that exist between CKD 
and other conditions in the chronic non-communicable disease 
category (e.g. diabetes), the NCDS complements the NCKDS with 
synergies between the initiatives recognised within its framework 
and recommendations. Action areas across the strategies include: 
risk reduction, health promotion and illness prevention; early 
detection and early treatment and management; management of 
advanced CKD and self-management; and, more specific to CKD, 
priorities for dialysis, organ donation and transplantation [69, 163]. 
With most of the underlying risk factors of CKD being primarily 
preventable, initiatives for risk reduction outlined by the NCDS 
and NCKDS include addressing the broad social determinants 
such as improvement of housing, education and employment 
opportunities, and the improvement, especially in remote areas, 
of affordable and healthy food choices and lifestyles [69, 163]. 
Prevention and risk reduction approaches are applicable across the 
continuum of chronic disease care, aiming to prevent the diseases 
themselves, or their progression and associated complications and 
co-morbidities [163]. Early diagnosis offers the potential for both 
disease specific and non-specific interventions to slow disease 
progression. Even if progression cannot be slowed, patients 
who have been diagnosed early have better survival rates when 
commencing KRT [165]. Risk reduction seeks to prioritise the quality 
of life of the patient as well as the ability for self-management. Early 
treatment of CKD complications can also significantly improve 
the long-term patient outcomes [164]. In line with the current 
national strategy documents, self-management stems from the 
understanding that capacity building and training would enhance 
the ability of people to take more care for themselves (diminishing 
the impact of risk factors) and to control the health services in 
their communities (community-controlled services and increase of 
Aboriginal health workers) [163].
Recommendations and lessons learned in 
the delivery of services to improve kidney 
health
Addressing the needs of populations who are considered 
disadvantaged, including Aboriginal and Torres Strait Islander 
people, is of particular importance to both the NCDS and 
NCKDS [69, 163]. Specifically, a key recommendation is the 
establishment of a national Aboriginal and Torres Strait Islander 
people chronic disease taskforce that transcends jurisdictional 
and community boundaries, as well as ensuring that all states/
territories work towards providing equitable access to all forms of 
KRT for Indigenous peoples. In addition, the NCDS highlighted the 
importance of monitoring and improving data quality as part of 
the strategy towards reducing the burden of chronic disease [163]. 
In response to these needs, the National Centre for Monitoring 
Chronic Kidney Disease was established in 2007 at the Australian 
Institute of Health and Welfare (AIHW) [166]. In 2009, the Centre 
released its first publication An overview of chronic kidney disease 
in Australia 2009, which includes up-to-date national data on CKD 
[3]. Despite these developments, the various recommendations put 
forward by these initiatives have yet to be endorsed in the way of 
formal policies. Consequently, there is currently no comprehensive 
CKD strategy in Australia. 
In 2010, the National Consumer Council of Kidney Health Australia7 
released a position statement calling for the Australian Government 
to take action on the shortfall of services for CKD [128]. Similar in 
aims to the NCKDS [69], the position statement outlines changes 
to achieve optimal kidney health services and care in Australia. The 
main components of the position statement include: recognition 
of the extent of CKD as a major chronic condition; development 
of a national program to increase awareness and early detection 
of CKD; the funding and resourcing of the development and 
delivery of high quality information and education services in CKD; 
patient support programs and the training and promotion of these 
services in the community [128].
Recent work conducted by the Renal Division at the George Institute 
has involved several studies aimed at improving kidney health. 
One project – The central Australia renal study - commissioned by 
the Office for Aboriginal and Torres Strait Islander (OATSIH) within 
the Department of Health and Ageing (DoHA) - aimed to provide 
data and recommendations that would inform governments in 
the cross-jurisdictional region to make evidence based policy 
decisions that better meet the health and service needs of 
Aboriginal dialysis patients in the region [167]. Another project, 
7	 The	National	Consumer	Council	of	Kidney	Health	Australia	advocates	
for	the	interests	of	kidney	patients	and	carers	throughout	Australia.	It	
comprises	kidney	patients	and	carers	working	together	to	improve	the	
quality	of	life	for	people	affected	by	kidney	disease	[128].
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commissioned by Kidney Health Australia, looking at the economic 
impact of the burden of CKD in Australia, aimed to establish the 
human and financial burden of CKD and to explore the cost-
effectiveness of screening and intervention to prevent progression 
of disease [168]. Ongoing projects in the Division include the 
Improving access to kidney transplants (IMPAKT) project aimed 
at identifying Indigenous Australians’ barriers to accessing kidney 
transplantation, and proposing strategies to reduce disparities 
in Indigenous Australians’ access to transplantation [117, 169]. 
In addition, findings from the Sharing the true stories (STTS), a 
longitudinal participatory action research (PAR) project (2001–05), 
provide support for solidifying policy in the kidney health arena 
[170]. Findings indicate that miscommunications and lack of 
shared understanding between Aboriginal client groups and 
health staff in renal and hospital services in the NT of Australia 
often limited patients’ opportunities and capacities to make 
informed choices about their health care. This suggests that, for 
there to be improvements in communication and health outcomes, 
fundamental change in the delivery of healthcare is required.
Other policies and one-off funding also continue to impact on 
the state of kidney health and related services in Australia. Under 
the umbrella of the Closing the gap strategy, which aims to 
reduce Indigenous disadvantages [171], the Council of Australian 
Governments (COAG) has shown commitment to reducing the 
factors that contribute to chronic disease [172, 173]. Similar to the 
NCDS, COAG focuses on a preventive health approach through 
the strengthening of primary health care as well as focussing on 
sustainability and cultural appropriateness [174]. In addition, the 
Australian Government has funded specific initiatives to reduce 
the incidence and spread of kidney diseases including: grants 
into kidney disease research via the National Health and Medical 
Research Council (NHMRC); the construction of a renal dialysis unit 
at the North Lakes Health Precinct in Queensland; funding towards 
improving the access of dialysis services in the Kimberley region 
of WA and for remote communities in the Northern Territory; and 
development of the Chronic Kidney Disease Monitoring Centre 
[175].
Concluding comments
Disorders of the kidneys and urologic system pose a significant, 
and frequently serious, public health threat for many Indigenous 
people [6, 7, 29]. ESKD, which underlies much of the renal 
morbidity and mortality seen in Indigenous communities, is the 
clear priority for the health system, but recurring epidemics of 
APSGN in northern Australia, the suspected high levels of UTIs, and 
the unusual epidemiology of urolithiasis also require appropriate 
attention. Continuing high rates of ESKD, the negative social 
consequences that accompany treatment, and the high cost of 
tertiary level medical care all illustrate the immediate need for a 
comprehensive health care approach that addresses both the 
medical and socioeconomic dimensions of this major problem [30, 
131, 159].
A range of biopsychosocial issues underlie the generally poor 
health status of many Indigenous people. Poverty, poor living 
conditions, limited access to medical care, and inadequate 
environmental sanitation contribute to high rates of kidney 
health disorders in many Indigenous communities [7, 49, 50]. The 
prevention, management and control of renal-urologic disorders 
will depend not only on effective, acceptable medical and surgical 
treatment, but, importantly, on preventive action to address the 
poor socioeconomic circumstances that underlie these conditions. 
Without adequate forward planning that considers service needs, 
service availability, and workforce projections, however, there 
will not be adequate resources to provide minimum standards 
of care for the growing number of Indigenous people dependant 
on dialysis [4, 153]. A comprehensive approach that addresses 
both the medical and socioeconomic dimensions of these health 
conditions is an immediate priority. 
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to-read and summarised material for students and the 
general community.
The HealthInfoNet encourages and supports information-
sharing among practitioners, policy-makers and others 
working to improve Indigenous health – its free on line 
yarning places enable people across the country to share 
information, knowledge and experience. The HealthInfoNet 
is funded mainly by the Australian Department of Health 
and Ageing. Its award-winning web resource (www.
healthinfonet.ecu.edu.au) is free and available to everyone.
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